Q-Med: Report on Operations 2002

UPPSALA, Sweden, Feb. 10, 2003 (PRIMEZONE) -- Q-Med (Stockholm:QMED):

 -- Sales increased during the year by 36 percent to SEK 517.8 (380.2) 
    million. During the fourth quarter turnover increased by 21 percent
    and amounted to SEK 148.3 (122.7) million.

 -- The corporate surplus value attributable to the intangible assets
    in Ixion Biotechnology, Inc. was written down by SEK 37.0 million.

 -- Operating income excluding items affecting income attributable to
    Ixion amounted to SEK 71.6 (55.2) million for 2002 and the operating 
    margin was 14 (15) percent. During the fourth quarter the 
    corresponding operating income amounted to SEK 26.8 (19.5) million. 
    Operating income including Ixion amounted to SEK 9.5 (23.7) million 
    for 2002.

 -- The Q-Med Group divests the North American business regarding the 
    esthetic products RESTYLANE, RESTYLANE Fine Lines and PERLANE for
    USD 160 million.

 Queries should be addressed to:
 Bengt Agerup, President and CEO
 +46 18-474 90 00 or +46 70-974 90 25

 Johan Hahnel, Director of Investor Relations and
  Corporate Communications
 +46 70-231 08 07

 This information was brought to you by Waymaker http://www.waymaker.net

 The following files are available for download:

 The full report

 The full report